To address the clinicopathological relevance of PERK activity, nine PERK-regulated genes, including GRP78, CHOP, GADD34, ATF4, SLC7A5, SPP1, COL5A2, HIF1A, and COL12A1, were selected as a signature, and tested its association with clinical outcomes of the cancers. This evidence concerns the gene HSPA5 and cancer.